Unicycive Approaches Its First Approval, But In A Competitive Space

The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.

(Shutterstock)
Key Takeaways
  • FDA approval of oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, is expected in June.

Unicycive Therapeutics was started by a single person, went public through an IPO in 2021, and four years later is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from New Products